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A b s t r a c t
Recent genetic studies have identified many 
differentially expressed genes in colorectal carcinomas. 
For validation of up-regulated genes in colorectal 
carcinomas, we performed an enzyme-linked 
immunosorbent assay. Candidate markers were 
selected from gene expression data for 40 colorectal 
cancers and 35 matched normal mucosal samples. 
Based on intensive filtering, 9 genes were selected for 
the further evaluations. Among them, macrophage 
migration inhibitory factor (MIF), inhibin βA, and 
chemokine ligand 10 were screened, and the results 
were compared with carcinoembryonic antigen (CEA) 
in serum samples of 129 patients with colon cancer and 
53 healthy control subjects. We found that the serum 
MIF level was significantly increased in patients with 
colorectal cancer. Compared with CEA, MIF was more 
sensitive in early cancer detection (47.3% vs 29.5%). 
However, the specificity was not as high as that of 
CEA (90.6% vs 100.0%). Our findings indicate that 
MIF may be used as a diagnostic marker in colorectal 
carcinomas.
Molecular genetic changes in colorectal carcinomas 
are among the best understood of such changes in common 
human cancers. This is a complex and dynamic process 
that is expected to involve many genetic changes and 
altered gene expressions. At the genetic level, inactiva-
tion of the APC/β-catenin genes, followed by activation of 
oncogenes and inactivation of additional tumor suppressor 
genes, is characteristic of colon cancers with chromosomal 
instability, and these changes are frequent in the majority 
of colon cancers. Inactivation of 1 of the genes respon-
sible for DNA nucleotide mismatch repair, which leads 
to extensive mutations in the genes containing repetitive 
DNA sequences, is characteristic of colon cancers with 
high microsatellite instability.1,2 In addition to these caus-
ative genetic changes in colon cancers, many differen-
tially expressed genes have been identified by functional 
genomic studies. Frequently reported up-regulated genes 
in colon cancer from DNA array studies include NME1, 
GNB2L1, CSE1L, SOX9, CCNB2, LAMR1, RAN, SLP1, 
and STK1.3-10 According to proteomic analysis, inorganic 
phosphatase, aldolase A, annexin 3 and 4, calgranulin B, 
and calreticulin are frequently reported to be up-regulated 
in colon carcinoma.11-20
Identification of altered gene expression profiles in 
colon cancers and the evaluation of these markers in body 
fluid could allow for early and efficient detection of colon 
cancer. To study this issue, we performed a serologic test 
for molecules up-regulated in colorectal carcinomas and 
known to be secreted in body fluid. We demonstrated the 
macrophage migration inhibitory factor (MIF) level as an 
early marker for the detection of colorectal carcinoma.
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Materials and Methods
Case Selection
A total of 40 colorectal carcinomas were included in 
this study for the discovery of up-regulated molecular mark-
ers in colon cancers. In 35 cases, grossly normal mucosa 
remote from the tumors was included as a control sample. 
All cases were selected randomly from consecutively iden-
tified cases at the Gastrointestinal Tumor Working Group 
Tissue Bank, Yonsei University Medical Center, Seoul, 
Korea, between December 1996 and December 2004, and 
from the Liver Cancer Specimen Bank (supported by the 
National Research Bank Program of the Korea Science 
and Engineering Foundation in the Ministry of Science 
& Technology). Authorization for the use of these tissues 
for research purposes was obtained from the institutional 
review board of Yonsei University College of Medicine. 
For validation of the selected markers in body fluid, fresh 
blood samples were collected from 129 patients with col-
orectal cancer and 53 people without colorectal cancers 
between January 2005 and February 2006. Informed con-
sent was received from each patient, and authorization of 
the study was obtained from the institutional review board. 
All of the patients with cancer and healthy control subjects 
underwent colonoscopy. In patients with colon cancer, 
blood samples were collected 1 day before surgery, and 
in control subjects, blood samples were collected in the 
outpatient clinic. All blood samples were delivered to the 
pathology laboratory within 30 minutes after collection, and 
the serum was separated. For the blood preparation, 3 mL 
of blood was collected in a serum separation tube, and the 
serum was prepared as previously described.21 The mean 
age of the patients with cancer was 63 years and of the con-
trol subjects was 60 years. Tumor stage and other data are 
listed in zTable 1z.
Gene Expression Analysis in Colon Cancer
RNA was extracted from fresh frozen tissue samples. 
Tumor specimens were microdissected on a cryostat and 
fractionated to enrich the tumor cell population. Microarray 
formulation and RNA preparation and hybridization have 
been previously reported.10 Briefly, 20 µg of total RNA 
extracted from microdissected frozen tissue samples was 
used as input for complementary DNA targets. The targets 
and Universal Human Reference (UHR) RNA (Stratagene, 
La Jolla, CA) were hybridized to an oligonucleotide microar-
ray containing 19,200 probe sets representing 18,664 unique 
genes (LEADS, Compugen, Rockville, MD), and the array 
was scanned using GenePix scanners (Molecular Devices, 
Toronto, Canada). Expression values for each gene were 
calculated by using GenePix Pro 4.0 analysis software. 
Of the 40 colorectal carcinomas and 35 matched normal 
mucosal samples, gene expression data from 17 colorectal 
carcinomas and 15 corresponding normal mucosal samples 
have been previously reported.10 The remaining 23 tumors 
zTable 1z
Comparison of Clinicopathologic Features of 129 Patients With Colorectal Cancer by Serum MIF and CEA Levels*
 Serum MIF Level (ng/mL) Serum CEA Level (ng/mL)
Feature >34.8 ≤34.8 P >6.3 ≤6.3 P
Age (y)   .5785   .1174
   <60 24 25  10 39 
   ≥60 37 43  28 52 
Sex   .7651   .3694
   M 36 38  19 55 
   F 25 30  19 36 
Stage   .0100   .0048
   I 15 6  1 20 
   II 21 21  11 31 
   III 15 24  12 27 
   IV 10 17  14 13 
Location   .4722   .6623
   Colon 34 42  25 51 
   Rectum 27 26  13 40 
Size (cm)   .9295   .9462
   <5 27 33  18 42 
   ≥5 34 35  20 49 
MSI status   .9659   .1032
   High 8 6  1 13 
   MSS and low 53 62  37 78 
CEA, carcinoembryonic antigen; MIF, macrophage migration inhibitory factor; MSI, microsatellite instability; MSS, microsatellite stable.
* Data are given as number of cases. Système International units for CEA are micrograms per liter; the conversion factor is 1.0.
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and 20 normal mucosal samples were analyzed by the same 
method and used in the subsequent data analysis.
Selection of Up-regulated Molecular Markers
Scanned images from each slide were initially analyzed 
by using GenePix, version 6.0, and spots of low quality were 
flagged out manually. Spot intensities were corrected for 
background and normalized for dye bias using LOWESS 
regression with the print-tip group correction. Then data were 
normalized with regard to the distribution of the ratios in each 
respective data set.
Because relative gene expression levels were measured 
with respect to UHR RNA, the data were restructured into 
relative gene expression levels in carcinomas with respect 
to normal mucosa by calculating the logarithmic difference 
between the ratio of each carcinoma vs UHR data and the 
average of the ratios from normal data vs UHR data. Gene 
expression ratios from data for 15 normal cases vs UHR 
data points from the first experiment were averaged into a 
representative normal level in data set A, and gene expression 
ratios from 20 normal cases vs UHR data points from the 
second experiment were averaged into a representative nor-
mal level in data set B. These relative gene expression levels 
were then averaged. The same method was used to calculate a 
representative tumor level of the first and second experiments: 
expression levels in 17 carcinomas (first experiment) and 23 
carcinomas (second experiment), respectively. Genes were 
considered up-regulated in carcinomas if the representative 
tumor level was greater than the representative normal level 
by at least 1.6-fold.
Enzyme-Linked Immunosorbent Assay
Serum concentrations of MIF, chemokine ligand 10 
(CXCL10), and inhibin A were measured by enzyme-
linked immunosorbent assay (ELISA) using the Human 
MIF Quantikine ELISA kit (R&D Systems, Minneapolis, 
MN), Human CXCL10/IP-10 Quantikine ELISA kit (R&D 
Systems), and Activin A assay kit (Oxford Bio-Innovation, 
Kidlington, England). All ELISAs were performed according 
to the manufacturers’ instructions.
Statistical Analysis
Statistical analysis was performed using MedCalc for 
Windows, version 9.3.3.0 (MedCalc Software, Mariakerke, 
Belgium). We constructed receiver operating characteristic 
(ROC) curves for each biomarker and combination of biomark-
ers to assess their diagnostic accuracy in distinguishing patients 
with colon cancer from control subjects. By using the ROC 
method, we calculated sensitivity, specificity, error rate, and 
area under the curve to determine the diagnostic accuracy of 
our findings. Analysis of a combination of carcinoembryonic 
antigen (CEA) and MIF was performed by logistic regression. 
We also calculated P values to determine whether serum levels 
of MIF and CEA depend on the histopathologic features of each 
case. The P values were calculated by using the χ2 test.
Results
Identification of Up-regulated Genes Encoding Secreted 
Proteins in Colorectal Carcinomas
We examined the relative expressions of each gene in 
the tumors in 2 ways. Relative gene expression in 40 carci-
nomas was compared first with respect to UHR RNA and 
then with respect to the average expression in 35 matched 
normal mucosal tissue samples. In 40 gene expression pro-
files, 655,929 values of 768,000 (19,200 spots × 40 samples) 
remained valid after data processing. Representative tumor 
levels of 456 genes were differentially expressed by at least 
1.6-fold, and 93 genes were predicted to be secreted by using 
the secreted protein database. Candidate genes were further 
narrowed by selecting those that were up-regulated by 1.6-fold 
in all 40 tumor samples. Only 69 genes met these criteria, and 9 
genes, including MIF, inhibin A, and CXCL10, were predicted 
to encode secreted proteins. These genes were finally selected 
as candidate tumor biomarkers in serum zTable 2z.
Validation of MIF, Inhibin A, and CXCL10 and 
Up-regulation of MIF in Serum of Patients With Colon 
Cancer
To examine the diagnostic values of up-regulated genes 
encoding secreted proteins, serum levels of MIF, CXCL10, and 
inhibin A were evaluated. These 3 genes were selected because 
commercial ELISA kits are available and known gene func-
tion is related to tumor development. Serum samples from 129 
patients with colon carcinoma and 53 control subjects were 
analyzed. MIF showed significantly increased serum levels 
in patients with colon cancer; the mean serum concentration 
was 35.2 ng/mL in patients with colon cancer and 21.3 ng/
mL in control subjects zFigure 1Az. There was no statistically 
significant difference in serum levels of CXCL10 and inhibin 
A between patients with colon cancer and control subjects. 
The mean serum value of CXCL10 was 0.16 ng/mL in patients 
with cancer and 0.15 ng/mL in control subjects, and the mean 
value of inhibin A was 0.35 ng/mL in patients with cancer and 
0.28 ng/mL in control subjects zFigure 1Bz and zFigure 1Cz.
Comparison of CEA and MIF as Diagnostic Markers
To evaluate the diagnostic value of MIF expression 
levels, we measured CEA levels in serum samples zFigure 
1Dz. When compared with levels of MIF in serum samples, 
MIF was more sensitive but its specificity was not as good 
as that of CEA. We determined cutoff values according to 
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zTable 2z
Nine Candidate Genes for Biomarker Validation*
UniGene Minimum Fold Maximum Symbol Gene Name Biologic Process
Hs.128553 1.2 18.9 233.9 WNT2 Wingless-type MMTV integration site Multicellular organismal development  
       family member 2 
Hs.413924 1 5.13 33.36 CXCL10 Chemokine (C-X-C motif) ligand 10 Cell surface receptor–linked signal  
        transduction
Hs.28792 1.1 5.1 59.3 INHBA Inhibin βA Cell surface receptor–linked signal  
        transduction
Hs.407995 1 2.03 4.5 MIF Macrophage migration inhibitory factor Cell proliferation; cell surface receptor– 
        linked signal transduction
Hs.521171 1 2.01 5.06 HIG2 Hypoxia-inducible protein 2 Response to stress
Hs.368131 1.1 1.89 3.92 ST7 Suppression of tumorigenicity 7 Unknown
Hs.84113 1.1 1.87 4.11 CDKN3 Cyclin-dependent kinase inhibitor 3 G1/S transition of mitotic cell cycle
Hs.507769 1.1 1.85 5.82 ALG5 Asparagine-linked glycosylation 5 Protein amino acid glycosylation  
       homolog 
Hs.517356 1.2 1.77 3.23 COL18A1 Collagen, type XVIII, α 1 Organ morphogenesis
MMTV, mouse mammary tumor virus.
* UniGene is an organized view of the transcription. Minimum represents the lowest fold change of expression level in colon cancer patient tissues compared with normal 
mucosal tissues from our microarray data. Fold represents the average fold change of expression level in colon cancer patient tissues compared with normal mucosal tissues 
from our microarray data. Maximum represents the highest fold change of expression level in colon cancer patient tissues compared with normal mucosal tissues from our 
microarray data.
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zFigure 1z Serum concentrations of macrophage migration inhibitory factor (MIF), CXCL10, inhibin A, and carcinoembryonic 
antigen (CEA) in 129 patients with colon cancer and 53 healthy control subjects by enzyme-linked immunosorbent assay. 
Black diamonds represent patients with cancer, and white diamonds represent control subjects. A, Serum MIF level. Mean 
concentration, 35.2 ng/mL in patients with cancer; 21.3 ng/mL in control subjects. B, Serum CXCL10 level. Mean concentration, 
0.16 ng/mL in patients with cancer; 0.15 ng/mL in control subjects. C, Serum inhibin A level. Mean concentration, 0.35 ng/mL 
in patients with cancer; 0.28 ng/mL in control subjects. D, Serum CEA level. Mean concentration, 10.1 ng/mL (10.1 µg/L) in 
patients with cancer; 2.5 ng/mL (2.5 µg/L) in control subjects.
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the ROC curve. When MIF and CEA levels were increased 
in cancer patients by a cutoff value of 34.8 ng/mL and 6.3 
ng/mL, respectively, the diagnostic sensitivity of MIF was 
47.3% and specificity was 90.6% zFigure 2Az and zTable 3z. 
For CEA, the diagnostic sensitivity was 29.5% and specificity 
was 100% zFigure 2Bz (Table 3). When diagnostic sensitivity 
according to tumor stage was compared, MIF was more useful 
than CEA for the detection of early stage cancer zFigure 2Cz 
(Table 3). The diagnostic sensitivity and specificity of MIF 
were 71.4% and 90.6% in stage I, 50% and 90.6% in stage II, 
38.5% and 90.6% in stage III, and 37.0% and 90.6% in stage 
IV, respectively. In contrast, the diagnostic sensitivity and 
specificity of CEA were 4.8% and 100% in stage I, 26.2% and 
100% in stage II, 30.8% and 100.0% in stage III, and 51.9% 
and 100.0% in stage IV, respectively.
The combination of these 2 markers showed greater sen-
sitivity and specificity zFigure 2Dz. Combined, sensitivity was 
61.2% and specificity was 92.5% (Table 3).
Discussion
In this study, we identified MIF as a candidate diagnostic 
biomarker for colorectal carcinomas. We identified a large 
number of genes that are up-regulated in colon cancer and 
have coding sequences for secreted proteins. Among these 
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zFigure 2z Comparison of carcinoembryonic antigen (CEA) and macrophage migration inhibitory factor (MIF) as diagnostic 
markers. The receiver operating characteristic (ROC) curve was used to determine the sensitivity, specificity, and SE of each 
marker. The SE, area under the curve (AUC), and significance level are summarized in Table 3. The ROC curve of each marker 
represents 90.6% specificity and 47.3% sensitivity for MIF according to a criterion of >34.8 ng/mL (A), 100% specificity and 
29.5% sensitivity for CEA according to a criterion of >6.3 ng/mL (6.3 µg/L; B), and comparison of MIF (solid line) and CEA 
(dotted line) using ROC methods (C). AUC of MIF, 0.761; AUC of CEA, 0.585. D, Combination of MIF and CEA; specificity, 
92.5%; sensitivity, 61.2%.
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proteins, we found that serum levels of MIF are frequently up-
regulated in patients with colon cancer compared with levels 
in control subjects. These data suggest that MIF may be useful 
as a diagnostic marker.
By DNA array analysis, we identified 65 genes that were 
up-regulated in all 40 carcinomas compared with matched 
normal-appearing mucosal samples. Many of these dys-
regulated genes were also reported to be up-regulated at the 
transcript level in previous reports.3-10 These genes belonged 
to the functional categories of nucleic acid metabolism (18 
genes, 29.5%), development (12 genes, 19.7%), cell cycle 
(10 genes, 16.4%), cell proliferation (10 genes, 16.4%), 
and organelle organization and biogenesis (7 genes, 11.5%) 
according to the functional bioinformatics database.22 Nine 
genes (about 13% of those detected) were identified as genes 
encoding secreted proteins in the secreted protein database. 
In this study, we selected MIF, CXCL10, and inhibin A for 
further serum evaluation.
MIF is a secretory cytokine and is known to contribute 
to the development and promotion of malignant tumors.23 
Overexpression of MIF has been reported in several types of 
cancer. MIF has been shown to promote malignant cell trans-
formation, enhance neovascularization, and inhibit tumor 
cell–specific cytolytic responses. Overexpression of MIF was 
reported to be related to poor outcome and early metastasis.23 
In the gastrointestinal tract, MIF is generally expressed and 
increased in sporadic colorectal adenomas and carcinomas.24 
In this study, we showed overexpression of MIF in early-
stage colon tumors and elevated serum MIF levels. These 
findings suggest that MIF may be a good candidate as a diag-
nostic marker for colon cancer. However, we also found a 
relatively broad range of MIF serum levels in healthy people 
without cancer. This breadth of the range might result from 
the fact that MIF expression is increased in inflammatory 
disorders, including inflammatory bowel disease, pancreati-
tis, and hepatitis.25 At present, we have no data concerning 
the serum MIF level in inflammatory diseases, but several 
previous studies showed that the serum MIF level is elevated 
in some inflammatory diseases.26-29 We believe that future 
studies should include and evaluate the serum MIF level from 
patients with inflammatory diseases as another control group 
to support our hypothesis. Moreover, it also should be noted 
that our small-scale study is not sufficient for clinical appli-
cation of MIF as a diagnostic marker. Future study should 
involve testing in an unrelated data set to validate this marker 
with large numbers of samples.
Two other markers selected for this study, inhibin A 
and CXCL10, were increased in colon cancer tissue sam-
ples, but their serum levels were not significantly increased 
compared with levels in control samples. CXCL10 is one of 
the chemokine, small cytokine–like secreted proteins30 and 
is reported to be overexpressed in several cancers. Recently, 
interactions between chemokines and chemokine receptors 
have been found to be important in the development and 
progression of cancer,31,32 and overexpression of CXCL10 
and its receptor, CXCR3, have been reported in breast can-
cer cells.33 Recently, in colorectal cancer, overexpression 
of CXCL10 and CXCR3 has been reported.34 Inhibin and 
activin are dimeric polypeptides. Inhibin A is a dimmer of 
inhibin βA and inhibin α. Inhibin and activin contribute 
to cell growth and development through binding to trans-
membrane receptors with serine/threonine kinase activity. 
Overexpression of activin A in stage IV colorectal carcinoma 
has been reported.35 Although we have demonstrated over-
expression of CXCL10 and inhibin A in colon cancer tissue 
samples, we could not demonstrate a statistically significant 
increase in serum levels in patients with colon cancer. These 
findings indicate that CXCL10 and inhibin A cannot be used 
as diagnostic markers in the serum. However, the possibility 
of prognostic or predictive markers of CXCL10 and inhibin 
A in cancer tissues remains and warrants further study. In 
addition, because the other 6 markers also have potential as 
colorectal cancer diagnostic biomarkers, evaluation of these 
markers might also be useful for biomarker discovery.
We compared MIF levels with CEA levels and found 
that the combination of these 2 markers can be used to 
increase the sensitivity of colorectal carcinoma diagnosis. 
CEA is a glycoprotein involved in cell adhesion that is nor-
mally produced during fetal development, but production 
stops before birth, and CEA is not usually present in the 
blood of healthy adults. However, it was been found that 
serum from people with colorectal, gastric, pancreatic, lung, 
and breast carcinoma has higher levels of CEA than that 
from healthy people. The previously reported sensitivity of 
zTable 3z
Summary of Receiver Operating Characteristic Curve Methods for MIF and CEA
    Area Under Significance Level P 
 Specificity (%) Sensitivity (%) SE the Curve  (Area = 0.5)
MIF 90.6 47.3 0.036 0.761 .0001
CEA 100.0 29.5 0.045 0.585 .0418
MIF and CEA 92.5 61.2 0.03 0.827 .0001
CEA, carcinoembryonic antigen; MIF, macrophage migration inhibitory factor.
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CEA is about 20% to 40%, and specificity is about 70% to 
100%. In accordance with previous reports, the serum CEA 
level is related to tumor progression, and, thus, evaluating 
serum CEA has limited value in detecting early-stage co-
lorectal cancer. We, therefore, suggest that the serum MIF 
level has diagnostic value in colon cancer detection alone 
and in combination with CEA.
We identified MIF as a candidate diagnostic marker for 
colorectal carcinoma. Moreover, the combination of MIF 
and CEA may be valuable in the early detection of colorectal 
carcinomas.
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